↑ トップへ　← 戻る

 Drug（薬物リスト） DrugBank | All Description Patterns

   e.g. "Sirolimus", "アダリムマブ"

A　B　C　D　E　F　G　H　 I 　J　K　L　M　N　O　P　Q　R　S　T　U　V　W　X　Y　Z　other

127 / 1,666 drugs found* Show info (disease name, etc.) on mouse-over.
 No.   DrugBank   薬物名（臨床試験情報から抽出）   KEGG DRUG *   KEGG GENES *   KEGG PATHWAY   指定難病告示番号 * 
 1   Abacavir  5件: Abacavir; Abacavir 300mg twice daily; Abacavir sulfate; Abacavir sulfate, lamivudine and zidovudine; Reverse transcriptase inhibitors: zidovudine, lamivudine, abacavir;   D00891
 D07057 		  -   -   4件:
2,
135,
265,
325
 2   Acetate  76件: 11c acetate; 11c-acetate; 20mg/0.5ml glatiramer acetate; 40 mg glatiramer acetate; [n-trans-3-hexenoyl] human growth hormone releasing factor (1-44) acetate; Abiraterone acetate; Acetate; Bazedoxifene acetate; Betamethasone sodium phosphate/betamethasone acetate (celestone® soluspan®), 30 mg im once a day for four days; Caspofungin acetate; Conventional glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone); Cortisone acetate; Cosyntropin acetate; Cyclophosphamide/glatiramer acetate; Delmitide acetate; Depot leuprolide acetate 3.75 mg; Desmopressin acetate; Desmopressin acetate trihydrate; Dirucotide acetate; Experimental glatiramer acetate; Flecainide acetate; Glatiramer acetate; Glatiramer acetate (copaxone®); Glatiramer acetate (db); Glatiramer acetate (ga); Glatiramer acetate (ga) 40 mg; Glatiramer acetate (ol); Glatiramer acetate 150mg enteric coated tablets; Glatiramer acetate 150mg enteric-coated (gastro-resistant) tablets; Glatiramer acetate 20 mg; Glatiramer acetate 20 mg, with mitoxantrone; Glatiramer acetate 20 mg/0.5 ml; Glatiramer acetate 40 mg; Glatiramer acetate injection with oral cetirizine hydrochloride; Glatiramer acetate with minocycline; Glatiramer acetate, (copaxone®); Glatiramer acetate, ifn-beta 1a (im), ifn-beta 1a (subcutaneous), and ifn-beta 1b; Glatiramer acetate, n-acetylcysteine; Gonadorelin acetate and triptorelin acetate; Human interferon beta-1a and glatiramer acetate; Hydrocortisone sodium acetate; L-lysyl-d-prolyl-l-threonine acetate; Lanreotide acetate; Leuprolide acetate (la); Leuprolide acetate 11.25 mg; Leuprolide acetate 3 month depot; Leuprolide acetate 30 mg; Leuprolide acetate 45 mg; Leuprolide acetate depot; Leuprorelin acetate; Leuprorelin acetate 3.75mg injection; Loestrin (norethindrone acetate and ethinyl estradiol); Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 µg ethinyl estradiol); Luphere depot 3.75mg(leuprolide acetate 3.75mg); Lupron (leuprolide acetate); Macimorelin acetate; Megestrol acetate; Megestrol acetate tablet; Nomegestrol acetate; Phosphate and betamethasone acetate, 2 ml.; Plovamer acetate; Prednisolone acetate; Prednisone acetate; Prednisone acetate tablets; Sodium acetate; Sodium-[o-[(2,6-dichlorophenyl)-amino]-phenyl]-acetate; Sotrastaurin (inn) acetate; Tetracosactide acetate; Tocopherol acetate; Tocopheryl acetate; Triptorelin acetate and gonadorelin acetate; Ulipristal acetate; Zinc acetate; Zinc acetate (20mg/d); Zinc acetate dihydrate; Zuretinol acetate;   -   -   -   40件:
1,
2,
6,
10,
13,
35,
40,
46,
49,
51,
60,
64,
70,
71,
73,
75,
76,
78,
81,
83,
85,
86,
88,
90,
96,
97,
113,
145,
156,
162,
171,
206,
222,
224,
225,
235,
265,
288,
298,
299
 3   Acetylcarnitine  1件: Acetylcarnitine;   -   -   -   3件:
2,
265,
298
 4   Aldesleukin  3件: Aldesleukin; Interleukin-2 (aldesleukin).; Low-dose aldesleukin (proleukin®);   D00748   3件: IL2RA, IL2RB, IL2RG   14件: Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Inflammatory bowel disease (IBD), JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Primary immunodeficiency, Th1 and Th2 cell differentiation, Th17 cell differentiation, Transcriptional misregulation in cancer, Viral protein interaction with cytokine and cytokine receptor   4件:
2,
49,
65,
97
 5   Anakinra  8件: Anakinra; Anakinra (kineret®); Anakinra (r-methuil-1ra); Anakinra / kineret; Anakinra and peg stnf-r1; Kineret® (anakinra); Kineret® or anakinra; Response to anakinra associated with methotrexate;   D02934   2件: IL1R1, IL1R2   15件: Amoebiasis, Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Inflammatory mediator regulation of TRP channels, MAPK signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Pathogenic Escherichia coli infection, Prostate cancer, Shigellosis, Th17 cell differentiation, Transcriptional misregulation in cancer   17件:
2,
13,
15,
19,
37,
41,
46,
49,
50,
56,
65,
84,
86,
106,
107,
266,
299
 6   Arimoclomol  1件: Arimoclomol;   D11374   -   -   3件:
2,
15,
19
 7   Arundic acid  1件: Arundic acid;   D06296   -   -   1件:
2
 8   Baclofen  5件: Aert, (r)-baclofen; Baclofen; Baclofen 20 mg; Baclofen ir; Rs-baclofen;   D00241   2件: GABBR1, GABBR2   7件: Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway   5件:
2,
10,
13,
18,
149
 9   Basiliximab  1件: Basiliximab;   D03058   1件: IL2RA   11件: Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor   7件:
2,
50,
65,
66,
97,
222,
228
 10   Betamethasone  6件: Betamethasone; Betamethasone acibutate; Betamethasone sodium phosphate/betamethasone acetate (celestone® soluspan®), 30 mg im once a day for four days; Intra-articular compound betamethasone; Intraarticular betamethasone; Phosphate and betamethasone acetate, 2 ml.;   D00244
 D00972
 D01357
 D01402
 D01637
 D02032
 D02286 		  1件: NR3C1   1件: Neuroactive ligand-receptor interaction   6件:
2,
46,
65,
90,
96,
235
 11   Biotin  2件: Biotin; D-biotin;   D00029   -   -   3件:
2,
13,
20
 12   Bosutinib  1件: Bosutinib;   D03252   2件: ABL1, SRC   45件: Adherens junction, Axon guidance, Bacterial invasion of epithelial cells, Bladder cancer, C-type lectin receptor signaling pathway, Cell cycle, Chemokine signaling pathway, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Epithelial cell signaling in Helicobacter pylori infection, ErbB signaling pathway, Estrogen signaling pathway, Fluid shear stress and atherosclerosis, Focal adhesion, GABAergic synapse, Gap junction, GnRH signaling pathway, Hepatitis B, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Inflammatory mediator regulation of TRP channels, Kaposi sarcoma-associated herpesvirus infection, MicroRNAs in cancer, Mitophagy - animal, Neurotrophin signaling pathway, Oxytocin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Platelet activation, Prolactin signaling pathway, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Shigellosis, Thyroid hormone signaling pathway, Tight junction, Tuberculosis, VEGF signaling pathway, Viral carcinogenesis, Viral myocarditis, Yersinia infection   2件:
2,
67
 13   Botulinum Toxin Type B  3件: Botulinum toxin type b; Botulinum toxin type b (2500 units / vial); Botulinum toxin type b (myobloc);   D02735   1件: SNAP25   2件: Insulin secretion, Synaptic vesicle cycle   3件:
2,
6,
51
 14   Botulinum toxin type A  3件: Botulinum toxin type a; Botulinum toxin type a (nabota®) injection into the gastrocnemius muscle; Clostridium botulinum toxin type a;   D00783   1件: SNAP25   2件: Insulin secretion, Synaptic vesicle cycle   13件:
2,
5,
6,
7,
13,
15,
17,
36,
51,
70,
113,
149,
226
 15   Butylphthalide  1件: Butylphthalide;   -   -   -   2件:
2,
6
 16   Caffeine  5件: Caffeine; Caffeine 100 mg; Caffeine 100-200 mg bid; Caffeine alkaloid; Dextromethorphan and caffeine;   D00528
 D01453 		  11件: ADORA1, ADORA2A, PDE1B, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A   22件: Alcoholism, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Glucagon signaling pathway, Insulin signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Olfactory transduction, Parathyroid hormone synthesis, secretion and action, Parkinson disease, Progesterone-mediated oocyte maturation, Purine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Taste transduction, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway   6件:
2,
6,
46,
78,
96,
97
 17   Cannabidiol  6件: Cannabidiol; Cannabidiol (cbd); Cannabidiol / dronabinol capsule 5 mg+2,5 mg; Cannabidiol capsule 5 mg; Cannabidiol oral solution; Cannabidiol tablet 10 mg;   D10915   2件: CNR1, CNR2   4件: Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis   14件:
2,
6,
13,
46,
95,
96,
97,
140,
144,
145,
157,
158,
193,
271
 18   Capsaicin  4件: Capsaicin; Capsaicin challenge; Capsaicin vapor; Qutenza (8% capsaicin);   D00250   1件: TRPV1   2件: Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction   6件:
2,
6,
19,
86,
113,
226
 19   Carbidopa  60件: Accordion pill carbidopa/levodopa; Accordion pill™ carbidopa/levodopa; Accordion pill™ carbidopa/levodopa 50/400 mg; Accordion pill™ carbidopa/levodopa 50/500 mg; Capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg); Carbidopa; Carbidopa 20 mg; Carbidopa 27.5 mg; Carbidopa 65 mg capsule; Carbidopa and levodopa 25mg/100mg; Carbidopa fu; Carbidopa levodopa; Carbidopa monohydrate; Carbidopa, levodopa, entacapone; Carbidopa- levodopa; Carbidopa-levodopa; Carbidopa/l-dopa; Carbidopa/l-dopa/entacapone; Carbidopa/levodopa; Carbidopa/levodopa, immediate release; Carbidopa/levodopa/entacapone; Comparator: carbidopa; Continuous intrajejunal infusion of levodopa-carbidopa; Controlled-release levodopa / carbidopa; Entacapone and carbidopa; Immediate release carbidopa/levodopa; Immediate release carbidopa/levodopa 25/100 mg; Levodopa and carbidopa; Levodopa and carbidopa sc solution; Levodopa and carbidopa solution for sc administration; Levodopa carbidopa (lc) oral encapsulated immediate release (ir) tablets; Levodopa carbidopa intestinal gel (lcig); Levodopa, carbidopa, entacapone; Levodopa, carbidopa, odm-104; Levodopa-carbidopa; Levodopa-carbidopa (lc) oral encapsulated immediate release (ir) tablets; Levodopa-carbidopa immediate release (lc-ir) tablets; Levodopa-carbidopa intestinal gel; Levodopa-carbidopa multilayer extended release tablet; Levodopa-carbidopa xl tablet (m); Levodopa-carbidopa-entacapone; Levodopa/carbidopa; Levodopa/carbidopa (4:1); Levodopa/carbidopa (sinemet); Levodopa/carbidopa 100/25; Levodopa/carbidopa hydrate; Levodopa/carbidopa solution; Levodopa/carbidopa(200mg/50mg); Levodopa/carbidopa/entacapone; Nd0612 (levodopa/carbidopa solution); Odm-101 105mg carbidopa; Odm-101 65mg carbidopa; Oral levodopa and carbidopa; Oral levodopa/carbidopa; Sinemet (levodopa/carbidopa); Sinemet plus (levodopa/carbidopa); Sinemet® controlled release (carbidopa/levodopa); Stalevo (levodopa/ carbidopa/ entacapone); Stalevo (levodopa/carbidopa/entacapona); Xp21279 and carbidopa (experimental);   D00558   1件: DDC   9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism   8件:
2,
4,
6,
13,
17,
90,
164,
201
 20   Carbonate ion  -  -   -   -   10件:
2,
13,
17,
19,
46,
75,
96,
127,
235,
299
 21   Ceftriaxone  1件: Ceftriaxone;   D00924
 D07659 		  -   -   3件:
2,
6,
97
 22   Celecoxib  7件: Celecoxib; Celecoxib (celebrex); Celecoxib 200 milligrams; Celecoxib 200mg capsule; Celecoxib 400 milligrams; Celecoxib, celebrex®; Fixed dose combination ciprofloxacin/celecoxib;   D00567   1件: PTGS2   20件: Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway   9件:
2,
3,
34,
46,
70,
89,
96,
161,
271
 23   Cimetidine  2件: Cimetidine; Cimetidine plus dexpramipexole;   D00295
 D03503 		  1件: HRH2   3件: Calcium signaling pathway, Gastric acid secretion, Neuroactive ligand-receptor interaction   1件:
2
 24   Ciprofloxacin  14件: Cipro (ciprofloxacin, bayq3939); Ciprofloxacin; Ciprofloxacin (cipro inhale, bayq3939); Ciprofloxacin (cipro, bayq3939); Ciprofloxacin (ciproxin); Ciprofloxacin dispersion for inhalation; Ciprofloxacin dpi; Ciprofloxacin for inhalation; Ciprofloxacin hydrochloride; Ciprofloxacin hydrochloride monohydrate; Fixed dose combination ciprofloxacin/celecoxib; Oral ciprofloxacin; Oral ciprofloxacin plus inhaled colistin; Po ciprofloxacin;   D00186
 D02216 		  -   -   5件:
2,
60,
96,
97,
299
 25   Colchicine  3件: Colchicine; Colchicine 1 mg oral tablet; Colchicine sprinkle capsules;   D00570   9件: TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8   3件: Gap junction, Pathogenic Escherichia coli infection, Phagosome   5件:
2,
42,
56,
93,
266
 26   Copper  4件: Copper; Copper histidinate; Copper histidine; Zinc and copper;   -   -   -   4件:
2,
169,
170,
171
 27   Corticotropin  8件: Corticotropin; Corticotropin releasing hormone; Corticotropin-releasing hormone; H.p. acthar gel (repository corticotropin injection); H.p. acthar® gel (repository corticotropin injection); Ovine corticotropin-releasing hormone (ocrh); Repository corticotropin injection; Repository corticotropin injection -treatment extension;   D00146   1件: MC2R   5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway   12件:
2,
13,
46,
49,
50,
66,
75,
78,
84,
145,
193,
222
 28   Creatine  4件: Creatine; Creatine monohydrate; Creatine-13c; Pyruvate, creatine, niacinamide;   -   -   -   12件:
1,
2,
5,
6,
8,
13,
46,
49,
50,
113,
156,
201
 29   Creatinine  1件: Creatinine;   D03600   -   -   3件:
2,
46,
60
 30   Cupric Chloride  -  D03612   -   -   4件:
2,
169,
170,
171
 31   Darunavir  1件: Darunavir;   D03656   -   -   1件:
2
 32   Deferiprone  7件: Deferiprone; Deferiprone (ferriprox); Deferiprone 600 mg delayed release tablet; Deferiprone 80 mg/ml oral solution; Deferiprone 80 mg/ml oral solution (ferriprox); Deferiprone oral solution; Ferrprox (deferiprone);   D07416   -   -   5件:
2,
6,
120,
122,
233
 33   Dexmedetomidine  8件: Dexmedetomidine; Dexmedetomidine 1; Dexmedetomidine 2; Dexmedetomidine 3; Dexmedetomidine and fentanyl; Dexmedetomidine group; Dexmedetomidine hydrochloride; Dexmedetomidine hydrochloride infusion;   D00514
 D01205 		  3件: ADRA2A, ADRA2B, ADRA2C   2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway   11件:
2,
4,
6,
21,
34,
70,
113,
212,
215,
226,
280
 34   Dexpramipexole  5件: Cimetidine plus dexpramipexole; Dexpramipexole; Dexpramipexole (dose 1); Dexpramipexole (dose 2); Dexpramipexole dichydrochloride;   D09886   5件: DRD1, DRD2, DRD3, DRD4, DRD5   11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway   1件:
2
 35   Dextran  4件: Dextran; Dextran sulfate sodium; Iron dextran; Iron(iii)- hydroxide dextran complex;   D00060   -   -   5件:
2,
62,
79,
96,
97
 36   Dextromethorphan  9件: Dextromethorphan; Dextromethorphan 30 mg; Dextromethorphan and caffeine; Dextromethorphan hbr and quinidine sulfate; Dextromethorphan hydrobromide; Dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg; Dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg; Dextromethorphan/quinidine 20mg/10mg (dm/q 20mg/10mg); Dimebon + dextromethorphan;   D00848
 D03742
 D03744 		  5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D   17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway   9件:
2,
6,
8,
13,
46,
78,
96,
97,
156
 37   Dolutegravir  1件: Dolutegravir;   D10066   -   -   1件:
2
 38   Dronabinol  4件: Cannabidiol / dronabinol capsule 5 mg+2,5 mg; Dronabinol; Dronabinol capsule 2,5 mg; Dronabinol capsule 2.5. mg;   D00306   2件: CNR1, CNR2   4件: Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis   5件:
2,
13,
46,
271,
298
 39   Edaravone  1件: Edaravone;   D01552   -   -   2件:
2,
22
 40   Eperisone  1件: Eperisone;   D01671
 D07898 		  -   -   1件:
2
 41   Erythropoietin  4件: Erythropoietin; Erythropoietin human recombinant (eporh); Recombinant human erythropoietin; Recombinant human erythropoietin(rhepo);   D03231   1件: EPOR   5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer   9件:
2,
6,
13,
22,
46,
47,
70,
95,
96
 42   Escitalopram  3件: Escitalopram; Escitalopram oxalate antidepressant; Oral escitalopram;   D02567
 D07704
 D07913 		  1件: SLC6A4   2件: Serotonergic synapse, Synaptic vesicle cycle   3件:
2,
6,
13
 43   Esketamine  2件: Esketamine; Esketamine hydrochloride;   D07283   5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D   17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway   3件:
2,
4,
70
 44   Ethanol  7件: Andrographis paniculata (ethanol extract); Ethanol; Ethanol (96 per cent); Ethanol 96% gel; Ethanol 98% solution; Ethanol bp; Ethanol gel;   D00068
 D02798
 D04855
 D06542 		  -   -   49件:
2,
11,
13,
14,
26,
35,
40,
41,
42,
43,
44,
45,
46,
49,
50,
51,
53,
58,
61,
63,
64,
65,
66,
81,
84,
85,
86,
88,
95,
96,
97,
113,
145,
162,
164,
222,
224,
228,
251,
279,
280,
283,
284,
285,
288,
298,
299,
300,
331
 45   Ezogabine  4件: Ezogabine; Ezogabine (us only); Ezogabine/retigabine; Retigabine/ezogabine;   D09569   5件: KCNQ1, KCNQ2, KCNQ3, KCNQ4, KCNQ5   6件: Adrenergic signaling in cardiomyocytes, Cholinergic synapse, Gastric acid secretion, Pancreatic secretion, Protein digestion and absorption, Vibrio cholerae infection   2件:
2,
144
 46   Fasudil  1件: Fasudil;   D07941   2件: ROCK1, ROCK2   22件: Axon guidance, Chemokine signaling pathway, Focal adhesion, Human cytomegalovirus infection, Leukocyte transendothelial migration, MicroRNAs in cancer, Oxytocin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Platelet activation, Proteoglycans in cancer, Regulation of actin cytoskeleton, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, TGF-beta signaling pathway, Tight junction, Vascular smooth muscle contraction, Wnt signaling pathway, Yersinia infection, cAMP signaling pathway, cGMP-PKG signaling pathway   1件:
2
 47   Febuxostat  1件: Febuxostat;   D01206   1件: XDH   5件: Caffeine metabolism, Drug metabolism - other enzymes, Metabolic pathways, Peroxisome, Purine metabolism   3件:
2,
6,
13
 48   Filgrastim  6件: Ep2006 (filgrastim); Filgrastim; Filgrastim (g-csf); Filgrastim hexal; Filgrastim, alemtuzumab; Granulocyte colony-stimulating factor (filgrastim);   D03235   1件: CSF3R   5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer   28件:
2,
6,
13,
16,
25,
26,
28,
34,
35,
36,
40,
41,
42,
45,
46,
49,
51,
60,
62,
65,
85,
96,
113,
164,
283,
284,
285,
331
 49   Fingolimod  6件: 0,5 mg fingolimod; Fingolimod; Fingolimod (fty720); Fingolimod 0.5 mg; Fingolimod 1.25 mg; Fingolimod hydrochloride;   D10001   1件: S1PR1   3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway   4件:
2,
13,
14,
156
 50   Glatiramer  23件: 20mg/0.5ml glatiramer acetate; 40 mg glatiramer acetate; Cyclophosphamide/glatiramer acetate; Experimental glatiramer acetate; Glatiramer; Glatiramer acetate; Glatiramer acetate (copaxone®); Glatiramer acetate (db); Glatiramer acetate (ga); Glatiramer acetate (ga) 40 mg; Glatiramer acetate (ol); Glatiramer acetate 150mg enteric coated tablets; Glatiramer acetate 150mg enteric-coated (gastro-resistant) tablets; Glatiramer acetate 20 mg; Glatiramer acetate 20 mg, with mitoxantrone; Glatiramer acetate 20 mg/0.5 ml; Glatiramer acetate 40 mg; Glatiramer acetate injection with oral cetirizine hydrochloride; Glatiramer acetate with minocycline; Glatiramer acetate, (copaxone®); Glatiramer acetate, ifn-beta 1a (im), ifn-beta 1a (subcutaneous), and ifn-beta 1b; Glatiramer acetate, n-acetylcysteine; Human interferon beta-1a and glatiramer acetate;   D04318   20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G   32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease (IBD), Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis   4件:
2,
13,
96,
156
 51   Gold  3件: Gold; Gold nanocrystals; Sodium aurothiomalate (intramuscular gold);   -   -   -   5件:
2,
6,
13,
46,
171
 52   Guanabenz  2件: Guanabenz; Guanabenz acetato;   D04375   3件: ADRA2A, ADRA2B, ADRA2C   2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway   2件:
2,
13
 53   Human Serum Albumin  4件: Human serum albumin; Human serum albumin (hsa) fused to recombinant human growth hormone (hgh); Human serum albumin (hsa) fused to somatropin; Recombinant human serum albumin (hsa) fused to human growth hormone (hgh);   D05424   -   -   3件:
2,
78,
96
 54   Human interleukin-2  2件: Human interleukin-2; Recombinant human interleukin-2 (rhil-2);   -   -   -   14件:
2,
13,
35,
46,
49,
51,
55,
56,
63,
65,
95,
96,
97,
271
 55   Ibudilast  1件: Ibudilast;   D01385   8件: CYSLTR1, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PTGIR   16件: Apelin signaling pathway, Calcium signaling pathway, Glucagon signaling pathway, Insulin signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action, Platelet activation, Progesterone-mediated oocyte maturation, Purine metabolism, Regulation of lipolysis in adipocytes, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway   2件:
2,
13
 56   Immune Globulin Human  -  -   -   -   20件:
2,
11,
13,
14,
17,
18,
35,
38,
39,
43,
45,
49,
50,
51,
63,
65,
85,
164,
296,
309
 57   Inosine  2件: 1) inosine 5'-monophosphate; Inosine;   D00054   -   -   4件:
2,
6,
13,
17
 58   Iodide I-123  -  -   -   -   2件:
2,
6
 59   Ioflupane I-123  1件: Ioflupane i 123;   D10014   -   -   3件:
2,
5,
6
 60   Lacosamide  1件: Lacosamide;   D07299   2件: SCN3A, SCN9A   1件: Taste transduction   3件:
2,
46,
149
 61   Lactose  3件: Lactose; Lactose in water; Lactose monohydrate;   D00046
 D03226 		  -   -   6件:
2,
6,
13,
97,
228,
310
 62   Lamivudine  7件: Abacavir sulfate, lamivudine and zidovudine; Combivir (zidovudine [azt] / lamivudine [3tc]); Lamivudine; Lamivudine/zidovudine; Lopinavir/ritonavir + zidovudine + lamivudine; Reverse transcriptase inhibitors: zidovudine, lamivudine, abacavir; Zidovudine/lamivudine;   D00353   -   -   7件:
2,
26,
42,
46,
135,
265,
325
 63   Lenograstim  3件: Granocyte - 34 million iu (lenograstim rhug-csf); Granocyte lenograstim; Lenograstim;   D03247   1件: CSF3R   5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer   3件:
2,
57,
65
 64   Leuprolide  11件: Depot leuprolide acetate 3.75 mg; Leuprolide; Leuprolide (gnrh agonists); Leuprolide acetate (la); Leuprolide acetate 11.25 mg; Leuprolide acetate 3 month depot; Leuprolide acetate 30 mg; Leuprolide acetate 45 mg; Leuprolide acetate depot; Luphere depot 3.75mg(leuprolide acetate 3.75mg); Lupron (leuprolide acetate);   D00989
 D08113 		  1件: GNRHR   2件: GnRH signaling pathway, Neuroactive ligand-receptor interaction   5件:
1,
2,
3,
51,
76
 65   Levetiracetam  1件: Levetiracetam;   D00709   1件: SV2A   1件: ECM-receptor interaction   4件:
2,
4,
6,
13
 66   Levodopa  87件: Accordion pill carbidopa/levodopa; Accordion pill™ carbidopa/levodopa; Accordion pill™ carbidopa/levodopa 50/400 mg; Accordion pill™ carbidopa/levodopa 50/500 mg; Capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg); Carbidopa and levodopa 25mg/100mg; Carbidopa levodopa; Carbidopa, levodopa, entacapone; Carbidopa- levodopa; Carbidopa-levodopa; Carbidopa/levodopa; Carbidopa/levodopa, immediate release; Carbidopa/levodopa/entacapone; Comparator: levodopa; Continuous intrajejunal infusion of levodopa-carbidopa; Controlled-release levodopa / carbidopa; Immediate release carbidopa/levodopa; Immediate release carbidopa/levodopa 25/100 mg; Intravenous levodopa; Iv levodopa; Levodopa; Levodopa (delivered intravenously); Levodopa (drug), intraduodenal administration; Levodopa (l-dopa); Levodopa (l-dopa) + standard care; Levodopa / benserazid; Levodopa / benserazide 200 + 50 mg; Levodopa 100 mg / benserazide 25 mg; Levodopa 100 mg a cap; Levodopa 125 mg a cap; Levodopa 150 mg a cap; Levodopa 25mg/100mg; Levodopa 75 mg a cap; Levodopa acute challenge; Levodopa and carbidopa; Levodopa and carbidopa sc solution; Levodopa and carbidopa solution for sc administration; Levodopa and decarboxylase inhibitor; Levodopa and domperidone; Levodopa benserazide madopar; Levodopa benserazide teva italia; Levodopa carbidopa (lc) oral encapsulated immediate release (ir) tablets; Levodopa carbidopa intestinal gel (lcig); Levodopa cr (controlled release); Levodopa cyclops; Levodopa dc.it fu; Levodopa dispersible; Levodopa infusion; Levodopa mr; Levodopa powder for inhalation; Levodopa test; Levodopa, carbidopa, entacapone; Levodopa, carbidopa, odm-104; Levodopa, decarboxylase inhibitor and comt inhibitor; Levodopa-carbidopa; Levodopa-carbidopa (lc) oral encapsulated immediate release (ir) tablets; Levodopa-carbidopa immediate release (lc-ir) tablets; Levodopa-carbidopa intestinal gel; Levodopa-carbidopa multilayer extended release tablet; Levodopa-carbidopa xl tablet (m); Levodopa-carbidopa-entacapone; Levodopa/benserazide; Levodopa/benserazide 100/25 mg; Levodopa/benzeraside; Levodopa/benzerazide; Levodopa/carbidopa; Levodopa/carbidopa (4:1); Levodopa/carbidopa (sinemet); Levodopa/carbidopa 100/25; Levodopa/carbidopa hydrate; Levodopa/carbidopa solution; Levodopa/carbidopa(200mg/50mg); Levodopa/carbidopa/entacapone; Levodopa/ddci; Nacom levodopa+cardidopa; Nd0612 (levodopa/carbidopa solution); Oral levodopa and carbidopa; Oral levodopa/carbidopa; Rasagiline mesylate with levodopa; Safinamide + levodopa; Sinemet (levodopa/carbidopa); Sinemet plus (levodopa/carbidopa); Sinemet® controlled release (carbidopa/levodopa); Stalevo (levodopa/ carbidopa/ entacapone); Stalevo (levodopa/carbidopa/entacapona); Tvp-1012 (1 mg/day) with levodopa; Tvp-1012 1mg with levodopa;   D00059   5件: DRD1, DRD2, DRD3, DRD4, DRD5   11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway   7件:
2,
4,
6,
17,
90,
164,
201
 67   Levosimendan  2件: Levosimendan; Oral levosimendan;   D04720   2件: PDE3A, PDE3B   11件: Apelin signaling pathway, Glucagon signaling pathway, Insulin signaling pathway, Metabolic pathways, Morphine addiction, Progesterone-mediated oocyte maturation, Purine metabolism, Regulation of lipolysis in adipocytes, Renin secretion, cAMP signaling pathway, cGMP-PKG signaling pathway   1件:
2
 68   Lipoic Acid  8件: Alpha lipoic acid; Alpha-lipoic acid; Alpha-lipoic acid and l-acetyl carnitine; Lipoic acid; Lipoic acid (la) with fish oil and la without fish oil; Lipoic acid and omega-3 fatty acids; Oral lipoic acid (la); R lipoic acid;   D00048
 D00086 		  -   -   5件:
2,
5,
13,
14,
20
 69   Lithium carbonate  1件: Lithium carbonate;   D00801   -   -   8件:
2,
5,
7,
8,
13,
17,
19,
127
 70   Lithium citrate  -  D04749   -   -   4件:
2,
5,
7,
8
 71   Masitinib  10件: Masitinib; Masitinib (3.0); Masitinib (4.5); Masitinib (6.0); Masitinib (ab1010); Masitinib 100mg; Masitinib 200mg; Masitinib 3 mg; Masitinib 6.0 mg; Masitinib mesylate;   D10229   1件: KIT   11件: Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer, Hematopoietic cell lineage, MAPK signaling pathway, Melanogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway   6件:
2,
5,
6,
13,
46,
96
 72   Medical Cannabis  -  -   -   -   6件:
2,
6,
13,
90,
96,
97
 73   Memantine  3件: Memantine; Memantine (ebixa); Memantine hydrochloride;   D04905
 D08174 		  5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D   17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway   7件:
2,
6,
8,
13,
49,
127,
205
 74   Methamidophos  -  -   -   -   12件:
2,
11,
13,
19,
46,
49,
58,
70,
85,
98,
298,
300
 75   Methylcobalamin  1件: Methylcobalamin;   D03246   -   -   1件:
2
 76   Methylprednisolone  29件: Administration of rituximab and methylprednisolone; Corticosteroid treatment (methylprednisolone or prednisolone); Cyclophosphamide, azathioprine,prednisone,methylprednisolone; Infliximab, methylprednisolone, methotrexate; Intravenous (i.v.) methylprednisolone 1000 mg, total 9; Intravenous methylprednisolone; Iv methylprednisolone; Iv methylprednisolone (steroids); Megadose oral methylprednisolone; Methotrexate + methylprednisolone; Methylprednisolone; Methylprednisolone (drug); Methylprednisolone (mp); Methylprednisolone (mp) or prednisone (pred); Methylprednisolone (or other glucocorticoid); Methylprednisolone bolus iv 15 mg/kg/d for 3 days.; Methylprednisolone hemisuccinate; Methylprednisolone iv; Methylprednisolone mylan générique; Methylprednisolone or budesonide; Methylprednisolone or prednisolone; Methylprednisolone pulse; Methylprednisolone sodium hemisuccinate; Methylprednisolone sodium succinate; Methylprednisolone(intravenously in the 1st-2nd-3rd month ); Methylprednisolone(intravenously in the 1st-3rd-5th month); Oral 5-asa+/-topical 5-asa+iv corticosteroids / po methylprednisolone; Prednisone (and methylprednisolone); Prednisone, methylprednisolone,cyclophosphamides;   D00407
 D00751
 D00979
 D05000
 D05001
 D05002 		  1件: NR3C1   1件: Neuroactive ligand-receptor interaction   36件:
2,
13,
25,
26,
35,
38,
39,
40,
41,
42,
43,
45,
46,
49,
50,
51,
60,
63,
64,
65,
66,
83,
84,
86,
96,
97,
145,
164,
220,
222,
224,
271,
283,
284,
285,
296
 77   Mexiletine  1件: Mexiletine;   D00639
 D08215 		  5件: SCN1A, SCN2A, SCN3A, SCN5A, SCN9A   3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction   5件:
1,
2,
10,
113,
114
 78   Midazolam  6件: Bms drug-drug interaction cocktail (montelukast, flurbiprofen, omeprazole, midazolam, and digoxin); Midazolam; Midazolam 2 mg; Midazolam 3 mg; Montelukast, flurbiprofen, midazolam, digoxin, pravastatin and bms-986142; S-ketamine & midazolam;   D00550
 D00696
 D05028 		  16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ   7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction   10件:
2,
3,
6,
13,
46,
70,
96,
97,
231,
298
 79   Minocycline  7件: Combination of minocycline and mtx or mtx alone; Glatiramer acetate with minocycline; Lovastatin, then minocycline/lovastatin; Minocycline; Minocycline 100 mg film-coated tablets; Minocycline hydrochloride; Minocycline, then minocycline/lovastatin;   D00850
 D05045 		  -   -   14件:
2,
6,
8,
13,
46,
84,
85,
90,
94,
162,
201,
206,
280,
299
 80   Moxifloxacin  5件: Avelox- moxifloxacin; Moxifloxacin; Moxifloxacin 400 mg; Moxifloxacin hydrochloride; Moxifloxacin infusion;   D00874
 D08237 		  -   -   8件:
2,
6,
46,
49,
85,
86,
240,
299
 81   Mycophenolate mofetil  17件: Azathioprine or mycophenolate mofetil; Cellcept (mycophenolate mofetil); Cyclosporine combine with mycophenolate mofetil; Immunosuppressive regime (azathioprine, mycophenolate mofetil or methotrexate); Mycophenolate mofetil; Mycophenolate mofetil (cellcept); Mycophenolate mofetil (mmf); Mycophenolate mofetil (mmf) 3 g/day; Mycophenolate mofetil 2 g/day; Mycophenolate mofetil [cellcept]; Mycophenolate mofetil orally 1000 mg twice a day (bid); Mycophenolate mofetil plus lower dose of prednisone; Mycophenolate mofetil(mmf); Mycophenolate mofetil, low dose steroid; Mycophenolate mofetil,methotrexate; Prednisolone and mycophenolate mofetil; Prednisone and mycophenolate mofetil;   D00752
 D05094
 D05095 		  2件: IMPDH1, IMPDH2   3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism   32件:
2,
11,
13,
14,
19,
20,
28,
35,
36,
42,
43,
45,
49,
51,
53,
60,
62,
65,
66,
85,
95,
96,
162,
164,
222,
224,
226,
234,
283,
284,
285,
300
 82   Mycophenolic acid  2件: Mycophenolic acid; Mycophenolic acid mofetil;   D05096   2件: IMPDH1, IMPDH2   3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism   34件:
2,
11,
13,
14,
19,
20,
28,
35,
36,
42,
43,
45,
49,
51,
53,
60,
62,
65,
66,
84,
85,
95,
96,
162,
164,
222,
224,
226,
228,
234,
283,
284,
285,
300
 83   Olanzapine  1件: Olanzapine;   D00454
 D06623 		  11件: ADRA1A, ADRA1B, ADRA1D, DRD2, DRD3, DRD4, HRH1, HTR2A, HTR2B, HTR2C, HTR6   16件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Alcoholism, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Salivary secretion, Serotonergic synapse, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway   2件:
2,
8
 84   Ozanezumab  1件: Ozanezumab;   D10331   1件: RTN4   1件: Alzheimer disease   1件:
2
 85   Palmidrol  -  D08328   -   -   1件:
2
 86   Perampanel  3件: 2 mg perampanel; 4 mg perampanel; Perampanel;   D08964   4件: GRIA1, GRIA2, GRIA3, GRIA4   13件: Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Long-term depression, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Transcriptional misregulation in cancer, cAMP signaling pathway   3件:
2,
6,
144
 87   Phenylbutyric acid  -  D05868   -   -   10件:
2,
3,
6,
8,
93,
94,
244,
251,
297,
299
 88   Phosphate ion  -  -   -   -   29件:
2,
3,
11,
12,
13,
28,
36,
46,
49,
51,
53,
60,
62,
65,
70,
78,
81,
83,
90,
96,
97,
164,
235,
256,
283,
284,
285,
286,
299
 89   Pimozide  4件: Pimozide; Pimozide 2 mg per day; Pimozide 2mg/day (current) or 4 mg/day (study initiation); Pimozide 4 mg per day;   D00560   2件: DRD2, DRD3   8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway   1件:
2
 90   Pioglitazone  6件: Actos (pioglitazone); Pioglitazone; Pioglitazone 15 mg; Pioglitazone and tretinoin; Pioglitazone or metformin; Tretinoin and pioglitazone hcl;   D00945
 D08378 		  1件: PPARG   9件: AMPK signaling pathway, Huntington disease, Longevity regulating pathway, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer   17件:
2,
6,
13,
15,
20,
46,
49,
65,
67,
78,
81,
86,
96,
229,
265,
298,
299
 91   Pleconaril  1件: Pleconaril;   D05528   -   -   1件:
2
 92   Pramipexole  20件: Dopamine agonists (pramipexole, ropirinole); Mirapex (pramipexole); P2b001 once daily (pramipexole 0.3 mg / rasagiline 0.75 mg),; P2b001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg),; Pramipexole; Pramipexole 0.125 mg tablets; Pramipexole 0.5 mg tablets; Pramipexole dihydrochloride; Pramipexole dihydrochloride extended-release tablets; Pramipexole dihydrochloride monohydrate; Pramipexole dihydrochloride monohydrate extended release; Pramipexole er; Pramipexole extended release; Pramipexole extended release tablet; Pramipexole immediate release; Pramipexole immediate release tablet; Pramipexole ir; Pramipexole or ropinirole; Pramipexole sr; R(+) pramipexole dihydrochloride monohydrate;   D00559
 D05575 		  3件: DRD2, DRD3, DRD4   8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway   2件:
2,
6
 93   Prednisone  57件: 0 mg prednisone; 5 mg prednisone; 5-aminosalicylic acid(5-asa) and/or prednisone; 5-asa, prednisone, azathioprine or remicade; Azathioprine/prednisone; Chinese herb prescription granule plus prednisone; Conventional glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone); Corticosteroids (prednisone or prednisolone); Cyclophosphamide, azathioprine,prednisone,methylprednisolone; Cyclophosphamide-prednisone-azathioprine; Glucocorticoid (prednisone or prednisolone); Granulocyte-colony stimulating factor (g-csf) and prednisone; Hormone (prednisone); Hydroxychloroquine + prednisone; Leflunomide 20 mg+prednisone 0.5mg/kg/d; Methylprednisolone (mp) or prednisone (pred); Mycophenolate mofetil plus lower dose of prednisone; Oral prednisone; Oral prednisone 5mg; Over encapsulated prednisone; Prednisone; Prednisone (and methylprednisolone); Prednisone + inhibace/cozaar; Prednisone - azathioprine; Prednisone 0,5 mg/kg orally on alternate days; Prednisone 15 mg; Prednisone 5 mg; Prednisone 7.5 mg; Prednisone acetate; Prednisone acetate tablets; Prednisone alone; Prednisone and cyclophosphamide; Prednisone and mycophenolate mofetil; Prednisone and ustekinumab treatment; Prednisone arrow 20mg; Prednisone arrow 5 mg; Prednisone capsules; Prednisone discontinuation; Prednisone in full dose; Prednisone or prednisolone; Prednisone plus cyclophosphamide; Prednisone tablets usp, 1 mg; Prednisone tablets usp, 2.5 mg; Prednisone tablets usp, 5 mg; Prednisone tablets, usp; Prednisone therapy and pharmacokinetic; Prednisone treatment; Prednisone, cyclophosphamide; Prednisone, fk506, mmf; Prednisone, methylprednisolone,cyclophosphamides; Prednisone/prednisolone; Rayos (delayed-release prednisone); Sotatercept with prednisone boost; Tacrolimus combined with prednisone; Thalidomide, cyclophosphamide and prednisone; Treatment systemic therapy (prednisone); Treatment with systemic therapy (prednisone);   D00473   1件: NR3C1   1件: Neuroactive ligand-receptor interaction   44件:
2,
11,
13,
14,
26,
35,
40,
41,
42,
43,
44,
45,
46,
49,
50,
51,
53,
61,
63,
64,
65,
66,
81,
84,
85,
86,
95,
96,
97,
113,
145,
162,
164,
222,
224,
228,
251,
283,
284,
285,
288,
299,
300,
331
 94   Pyrimethamine  2件: Fansidar (pyrimethamine and sulfadoxine); Pyrimethamine;   D00488   -   -   4件:
2,
4,
19,
65
 95   Quinidine  5件: Dextromethorphan hbr and quinidine sulfate; Dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg; Dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg; Dextromethorphan/quinidine 20mg/10mg (dm/q 20mg/10mg); Quinidine;   D00642
 D00643
 D02272
 D08458 		  5件: SCN1A, SCN2A, SCN3A, SCN5A, SCN9A   3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction   3件:
2,
8,
13
 96   Rabeprazole  1件: Rabeprazole;   D00724
 D08463 		  2件: ATP4A, ATP4B   4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation   2件:
2,
51
 97   Ranolazine  7件: Ranolazine; Ranolazine 1000 mg; Ranolazine 1000 mg pr tablets; Ranolazine 500 mg; Ranolazine 500 mg pr tablets; Ranolazine 750 mg pr tablets; Ranolazine pr (prolonged-release) 500 mg 1 tablet bis in die and 750 mg 1 tablet bis in die;   D05700
 D05701 		  -   -   6件:
2,
58,
86,
113,
114,
130
 98   Rasagiline  16件: 1.0 mg rasagiline mesylate; Group r rasagiline; Group r+ad rasagiline + antidepressant; P2b001 once daily (pramipexole 0.3 mg / rasagiline 0.75 mg),; P2b001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg),; Rasagiline; Rasagiline 1 mg capsule; Rasagiline 1mg tablet; Rasagiline 2 mg tablet; Rasagiline mesilate; Rasagiline mesylate; Rasagiline mesylate 1.0 mg; Rasagiline mesylate plus mirapex; Rasagiline mesylate with levodopa; Rasagiline mesylate with requip; Rasagiline tablets;   D02562
 D08469
 D10829 		  1件: MAOB   13件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism   4件:
2,
5,
6,
17
 99   Reldesemtiv  -  D11363   1件: TNNC2   1件: Calcium signaling pathway   2件:
2,
3
 100   Ribavirin  1件: Ribavirin;   D00423   -   -   2件:
2,
96
 101   Riluzole  5件: Riluzole; Riluzole 50 mg; Riluzole 50 mg (part b); Riluzole oral soluble film; Riluzole oral soluble film (rosf) 50 mg;   D00775   14件: GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D   20件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term depression, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Retrograde endocannabinoid signaling, Systemic lupus erythematosus, Transcriptional misregulation in cancer, cAMP signaling pathway   7件:
2,
3,
5,
8,
13,
17,
206
 102   Ritonavir  9件: Atazanavir (atv) + ritonavir (rtv), continuation of backbone 2 nucleoside reverse transcriptase inhibitor (nrtis); Atazanavir/ritonavir; Lopinavir / ritonavir; Lopinavir/ritonavir; Lopinavir/ritonavir + nevirapine; Lopinavir/ritonavir + zidovudine + lamivudine; Ritonavir; Ritonavir (norvir); Saquinavir and ritonavir;   D00427   -   -   5件:
2,
86,
130,
265,
299
 103   Scopolamine  1件: Scopolamine;   D00138   5件: CHRM1, CHRM2, CHRM3, CHRM4, CHRM5   11件: Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway   1件:
2
 104   Serine  4件: D-serine; D-serine (~2g/day); L-serine; Serine;   D00016   -   -   3件:
2,
6,
86
 105   Serotonin  2件: Selective serotonin uptake inhibitors (ssri); Serotonin;   -   -   -   1件:
2
 106   Sirolimus  14件: Rapamycin, sirolimus; Sirolimus; Sirolimus (formerly known as rapamycin); Sirolimus 0,1% crème; Sirolimus 0.2%; Sirolimus 0.4%; Sirolimus 2 mg; Sirolimus 2%; Sirolimus and hydroxychloroquine; Sirolimus oral liquid product 1mg/ml; Sirolimus, 2%; Skincerity plus sirolimus/rapamycin; Skinercity plus sirolimus/rapamycin; Topical 0.1% sirolimus;   D00753   1件: MTOR   43件: AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway   36件:
2,
13,
15,
17,
34,
35,
36,
46,
49,
51,
60,
61,
62,
63,
65,
66,
67,
85,
86,
89,
96,
98,
137,
157,
158,
192,
222,
256,
277,
278,
279,
280,
281,
283,
285,
331
 107   Somatotropin  2件: Recombinant human somatotropin; Somatotropin;   D02691   1件: GHR   5件: Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway   18件:
2,
3,
13,
19,
46,
74,
75,
78,
96,
113,
191,
193,
195,
236,
265,
274,
276,
299
 108   Sulfate ion  -  -   -   -   22件:
2,
6,
11,
13,
26,
34,
36,
46,
49,
60,
61,
64,
66,
79,
86,
96,
222,
226,
265,
296,
297,
299
 109   TRO19622  2件: Olesoxime (tro19622); Tro19622;   -   -   -   3件:
2,
3,
13
 110   Tacrolimus  13件: Busulfan/fludarabine phosphate/tacrolimus/methotrexate/g-csf; Interferon beta-1b and tacrolimus; Lcp-tacro (tacrolimus); Non-mtx dmards (e.g. sulfasalazine, leflunomide, bucillamine, tacrolimus, or mizoribin); Rectal tacrolimus; Tacrolimus; Tacrolimus (prograf®); Tacrolimus and mmf; Tacrolimus capsule; Tacrolimus capsules; Tacrolimus combined with prednisone; Tacrolimus prolonged-release hard capsules; Tacrolimus with methotrexate;   D00107
 D08556 		  5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2   30件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway   30件:
2,
11,
13,
36,
46,
49,
50,
51,
53,
60,
61,
62,
65,
66,
85,
86,
95,
96,
97,
113,
151,
158,
164,
222,
224,
226,
228,
283,
284,
299
 111   Talampanel  1件: Talampanel;   D02696   4件: GRIA1, GRIA2, GRIA3, GRIA4   13件: Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Long-term depression, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Transcriptional misregulation in cancer, cAMP signaling pathway   2件:
2,
6
 112   Tamoxifen  3件: Tamoxifen; Tamoxifen 40 mg daily for one year; Tamoxifen citrate;   D00966
 D08559 		  2件: ESR1, ESR2   9件: Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway   4件:
2,
86,
113,
227
 113   Tauroursodeoxycholic acid  2件: Tauroursodeoxycholic acid; Tauroursodeoxycholic acid capsules;   -   -   -   4件:
2,
13,
93,
299
 114   Tenofovir  10件: Emtricitabine (ftc)/tenofovir disoproxil (tdf); Emtricitabine/tenofovir; Tenofovir; Tenofovir (tdf) and emtricitabine (ftc); Tenofovir alafenamide; Tenofovir alafenamide (taf); Tenofovir df; Tenofovir disoproxil; Tenofovir disoproxil fumarate; Tenofovir-emtricitabine;   D06074   -   -   5件:
2,
25,
93,
265,
325
 115   Tenofovir alafenamide  2件: Tenofovir alafenamide; Tenofovir alafenamide (taf);   D10428   -   -   1件:
2
 116   Testosterone  7件: Nebido® testosterone undecanoate 1000 mg/4 ml solution for injection; Sustanon (testosterone); Testosterone; Testosterone enanthate; Testosterone plus somatropin; Testosterone undecanoate; Transdermal testosterone gel;   D00075
 D00957
 D00958
 D00959
 D06085
 D06087 		  1件: AR   3件: Oocyte meiosis, Pathways in cancer, Prostate cancer   7件:
1,
2,
3,
13,
78,
113,
265
 117   Thalidomide  9件: Fpf 300 (thalidomide); Melphalan, thalidomide and dexamethasone; Thalidomide; Thalidomide (drug); Thalidomide 100mg; Thalidomide 150mg; Thalidomide celgene - 50 mg capsula rigida - uso orale - blister (pvc/pe/aclar/alu) 28 capsule; Thalidomide pharmion; Thalidomide, cyclophosphamide and prednisone;   D00754   1件: TNF   61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway   18件:
2,
16,
20,
28,
49,
51,
53,
65,
84,
85,
94,
96,
97,
227,
271,
280,
298,
331
 118   Tirasemtiv  1件: Tirasemtiv;   D10327   -   -   1件:
2
 119   Tocilizumab  25件: Abatacept, rituximab or tocilizumab; Corticoids+ tocilizumab 8mg/kg/4 weeks; Decrease tocilizumab, abatacept; Inn-tocilizumab; Intra-articular tocilizumab; Mra (tocilizumab); Mra(tocilizumab); Subcutaneous tocilizumab; Tocilizumab; Tocilizumab (actemra®); Tocilizumab (mra-sc); Tocilizumab + glucocorticoids (gcs); Tocilizumab + methotrexate(mtx); Tocilizumab 162 mg; Tocilizumab 162mg/0.9ml jeringa sc; Tocilizumab [roactemra/actemra]; Tocilizumab [roactemra]; Tocilizumab infusion roacemtra (eu); Tocilizumab injection; Tocilizumab prefilled syringe; Tocilizumab sc; Tocilizumab sc 162 mg/0.9 ml prefilled syringe with safety device (pfs); Tocilizumab treatment; Tocilizumab+methotrexate(mtx); Tocilizumab, abatacept;   D02596   1件: IL6R   11件: Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease (NAFLD), PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor   16件:
2,
13,
40,
41,
43,
46,
50,
51,
53,
54,
55,
86,
107,
266,
271,
331
 120   Tretinoin  3件: Pioglitazone and tretinoin; Tretinoin; Tretinoin and pioglitazone hcl;   D00094   3件: PML, RARA, RARB   12件: Acute myeloid leukemia, Endocytosis, Estrogen signaling pathway, Gastric cancer, Herpes simplex virus 1 infection, Influenza A, Non-small cell lung cancer, Pathways in cancer, Small cell lung cancer, Th17 cell differentiation, Transcriptional misregulation in cancer, Ubiquitin mediated proteolysis   5件:
2,
63,
75,
94,
231
 121   Triheptanoin  4件: Triheptanoin; Triheptanoin 1g/kg/day; Triheptanoin oil; Ux007 (triheptanoin);   D11465   -   -   10件:
2,
8,
120,
149,
156,
248,
256,
257,
317,
324
 122   Ubidecarenone  -  D01065   -   -   12件:
2,
5,
6,
8,
10,
46,
57,
86,
113,
193,
214,
215
 123   Valproic Acid  3件: Valproic acid; Valproic acid (vpa); Valproic acid and levocarnitine;   D00399   7件: ABAT, ALDH5A1, CACNA1G, CACNA1H, CACNA1I, GAD1, GAD2   17件: Alanine, aspartate and glutamate metabolism, Aldosterone synthesis and secretion, Butanoate metabolism, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, GABAergic synapse, GnRH secretion, MAPK signaling pathway, Metabolic pathways, Propanoate metabolism, Taurine and hypotaurine metabolism, Type I diabetes mellitus, Type II diabetes mellitus, Valine, leucine and isoleucine degradation, beta-Alanine metabolism   14件:
2,
3,
5,
8,
26,
34,
65,
89,
90,
102,
222,
233,
256,
331
 124   Vitamin E  8件: Coenzyme q10 with vitamin e; Omega-3 and vitamin e supplementation; Vitamin c 10mg/kg vitamin e 10 mg/kg; Vitamin e; Vitamin e - tgps; Vitamin e 800iu; Vitamin e supplement; Vitamin e/selenium;   D02331   -   -   12件:
2,
6,
13,
20,
46,
49,
90,
96,
97,
206,
299,
317
 125   Water  13件: 15 o water; 15-o labeled water; 5% glucose water solution; Dextrose, 5% in water; High water intake; Lactose in water; Pl 12185/0002 & pl 12185/0005(water for injection); Pseudoephedrine + 480 ml water; Pseudoephedrine + 50 ml water; Water; Water for injection; Water for injections; Water for injections, ep;   D00001   -   -   22件:
2,
5,
6,
13,
17,
19,
28,
35,
46,
53,
57,
63,
65,
67,
78,
84,
97,
193,
226,
271,
278,
299
 126   Zinc  8件: Adeno-associated virus serotype 2/6 encoding left side-zinc finger nuclease (zfn1), sb-a6p-zleft vector; Adeno-associated virus serotype 2/6 encoding right side-zinc finger nuclease (zfn2), sb-a6p-zright vector; Zinc; Zinc acetate; Zinc acetate (20mg/d); Zinc acetate dihydrate; Zinc and copper; Zinc gluconate;   -   -   -   4件:
2,
19,
171,
299
 127   Zinc chloride  -  D02058   -   -   4件:
2,
19,
171,
299

先頭へ